References:
  1. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547–3556. doi: 10.1093/eurheartj/eht290
  2. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al; MADIT-CRT Investigators. Effectiveness of cardiac resynchronization therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123:1061–1072. doi: 10.1161/ CIRCULATIONAHA.110.960898.
  3. Normand C, Linde C, Singh J, Dickstein K. Indications for cardiac resynchronization therapy: a comparison of the major international guidelines. JACC Heart Fail 2018;6:308–316.
  4. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, Shinn T, Sutton MS; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013;368:1585–1593.
  5. Vamos M, Erath JW, Bari Z, Vagany D, Linzbach SP, Burmistrava T, Israel CW, Duray GZ, Hohnloser SH (2017). Effects of upgrade versus de novo cardiac resynchronization therapy on clinical response and long-term survival: results from a multicenter study. Circ Arrhythmia Electrophysiol 10(2):e004471. https://doi.org/10.1161/circep.116.004471
  6. Cheung JW, Ip JE, Markowitz SM, Liu CF, Thomas G, Feldman DN, et al. Trends and outcomes of cardiac resynchronization therapy upgrade procedures: a comparative analysis using a United States National Database 2003-2013. Heart Rhythm (2017), doi: 10.1016/j.hrthm.2017.02.017.
  7. Martinelli Filho M, Peixoto GL, Siqueira SF, Nishioka ASD, Pedrosa ALA, Teixeira RA. A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy. Europace 2018;20:1813–8.
  8. Passos LCS, Vieira de Melo RM, Lira YM, Oliveira NFC, Trindade TC, Carvalho W, et al . Chagas disease is associated with a poor outcome at 1-year follow-up after cardiac resynchronization therapy. Rev. Assoc. Med. Bras.  [Internet]. 2019  Nov [cited  2020  May  12] ;  65( 11 ): 1391-1396. https://doi.org/10.1590/1806-9282.65.11.1391.
  9. St. John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107(15):1985–90.
  10. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med. 2009;361(14):1329–38.
  11. Bogale N, Witte K, Priori S, Cleland J, Auricchio A, Gadler F, et al. The European Cardiac Resynchronization Therapy Survey: comparison of outcomes between de novo cardiac resynchronization therapy implantations and upgrades. Eur J Heart Fail 2011;13:974-83.
  12. Kosztin A, Vamos M, Aradi D, Schwertner WR, Kovacs A, Nagy KV, et al. De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. Heart Fail Rev. 2018;23(1):15‐26. doi:10.1007/s10741-017-9652-1.
  13. Beca B, Sapp JL, Gardner MJ, Gray C, AbdelWahab A, MacIntyre C, et al. Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy. CJC Open. 2019;1(2):93‐99. Published 2019 Mar 6. doi:10.1016/j.cjco.2019.02.002
  14. Linde CM, Normand C, Bogale N, Auricchio A, Sterlinski M, Marinskis G, et al. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. Eur J Heart Fail. 2018;20(10):1457‐1468. doi:10.1002/ejhf.1235
  15. Mady C, Cardoso RH, Barreto ACP, Da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy. Circulation. 1994; 90: 3098-102.
  16. Silva CP, Del Carlo CH, Oliveira MT Junior, Scipioni A, Strunz-Cassaro C, Ramirez JA, et al. Why do patients with chagasic cardiomyopathy have worse outcomes than those with non-chagasic cardiomyopathy? Arq Bras Cardiol. 2008;91(6):358–62.
  17. Oliveira-Filho J, Viana LC, Vieira-de-Melo RM, Faiçal F, Torreão JA, Villar FA, et al.. Chagas disease is an independent risk factor for stroke: baseline characteristics of a Chagas Disease cohort. Stroke. 2005; 36:2015–2017.